RT Journal Article
SR Electronic
T1 Lung Cancer vs. „Young Cancer“ – Is There a Difference?
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3851
DO 10.1183/13993003.congress-2021.PA3851
VO 58
IS suppl 65
A1 Monika Bratová
A1 Karolina Hurdalkova
A1 Marie Drosslerova
A1 Juraj Kultan
A1 Matyas Wanke
A1 Martin Svaton
A1 Kristian Brat
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3851.abstract
AB Introduction: Lung cancer is the leading cause of death among all cancer diseases worldwide. Most of patients were in the age group of 65-69 years, however we also experience young patients with lung cancer. This subgroup is rather small, but it deserves major attention.Aims: Our study focused on patients aged under 40 years with lung cancer diagnosed between 2011-18 in five pneumo-oncology centers in Czechia. Our aim was to analyze demographic and tumor characteristics, treatment and survival outcomes contraty to the older patients (cohort 2).Methods: Basic characteristics were described by standard descriptive statistics. Chi-squared test and Fisher exact test were used for comparison of variables between cohorts. Kaplan-Meier survival analysis was used to estimate PFS and OS. As a level of statistical significance, p value <0.05 was used.Results: We found 66 patients under 40ty with lung cancer – 61 patients with NSCLC and 5 patients with SCLC, only NSCLC patients were underwent to a further analysis (cohort 1). This cohort counts 50, 8% of men, mean age 34,6 years, 54,1% of non-smokers (vs 79,7% in cohort 2, p <0.001), mainly in a good performance status. About 82% were in IV stage (vs 67,7%, p<0.001). Adenocarcinomas dominated (75,4%), 16,3% were EGFR positive (vs 21,6% in cohort 2), 25,6% ALK positive (vs 8,5% in cohort 2). Median PFS of young lung cancer patients was 3,7 months (vs 4,9 months, p = 0,006), OS reached 11,7 months (vs 22,3 months, p <0.001).Conclusions: Patients under 40ty have much worse prognosis than older patients with lung cancer. The investigation of a different etiopathogenesis of their disease is needed as well as a new approach both in diagnosis and treatment.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3851.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).